Liposphere develops CCoat®, a biolubricant boundary coating technology that reduces friction and wear on biological joints and artificial medical surfaces. Their platform offers injectable solutions for intra-articular application to treat osteoarthritis and can enhance the performance of implants and catheters.
Funding
Funding not disclosed
Founders
Product
Problem
Mechanically stressed biological joints, such as the knee and hip, experience significant friction and wear, leading to conditions like osteoarthritis and reduced mobility. Similarly, artificial medical devices like implants and catheters can suffer from suboptimal functionality due to surface friction.
Solution
Liposphere has developed the CCoat® platform, a proprietary technology that creates advanced biolubricant boundary coatings for both biological and artificial surfaces. This platform offers injectable solutions for intra-articular application, designed to reduce friction and wear within joints. Beyond direct joint treatment, CCoat® can also be applied to synthetic medical surfaces, enhancing their performance and durability. The technology leverages lipid-based and water-based biomaterials to provide superior lubrication and can potentially encapsulate active pharmaceutical ingredients for targeted delivery.
Target Audience
Liposphere targets healthcare providers and medical device manufacturers seeking innovative solutions for joint health and improved performance of implantable and insertable medical devices.
Features
- CCoat® platform for creating biocompatible boundary coatings.
- Intra-articular injectable formulation for treating knee osteoarthritis.
- Reduces friction and wear on biological cartilage surfaces.
- Capable of coating artificial medical surfaces, including orthopaedic implants and catheters.
- Potential for encapsulating and delivering active pharmaceutical ingredients.
- Utilizes advanced lipid-based and water-based biomaterial formulations.